231 related articles for article (PubMed ID: 28911730)
1. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.
Resteghini C; Cavalieri S; Galbiati D; Granata R; Alfieri S; Bergamini C; Bossi P; Licitra L; Locati LD
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):349-361. PubMed ID: 28911730
[TBL] [Abstract][Full Text] [Related]
2. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
[TBL] [Abstract][Full Text] [Related]
3. Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.
Klein Hesselink EN; Steenvoorden D; Kapiteijn E; Corssmit EP; van der Horst-Schrivers AN; Lefrandt JD; Links TP; Dekkers OM
Eur J Endocrinol; 2015 May; 172(5):R215-25. PubMed ID: 25572389
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect.
Højer Wang L; Wehland M; Wise PM; Infanger M; Grimm D; Kreissl MC
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768635
[TBL] [Abstract][Full Text] [Related]
5. Drug safety evaluation of lenvatinib for thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
7. Management of treatment-related toxicities in advanced medullary thyroid cancer.
Tsang VHM
Curr Opin Oncol; 2019 May; 31(3):236-242. PubMed ID: 30865134
[TBL] [Abstract][Full Text] [Related]
8. Management of treatment-related toxicities in advanced medullary thyroid cancer.
Brose MS; Bible KC; Chow LQM; Gilbert J; Grande C; Worden F; Haddad R
Cancer Treat Rev; 2018 May; 66():64-73. PubMed ID: 29704768
[TBL] [Abstract][Full Text] [Related]
9. Gastropharyngeal Anastomotic Leak in Medullary Thyroid Carcinoma Following Initiation of a Tyrosine Kinase Inhibitor: A Case Report of an Unusual Side Effect of Cabozantinib.
Ackerman J; Kent S; Walker P
Ann Otol Rhinol Laryngol; 2020 Jul; 129(7):657-661. PubMed ID: 32037846
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
11. Proteinuria is a late-onset adverse event in patients treated with cabozantinib.
Cappagli V; Moriconi D; Bonadio AG; Giannese D; La Manna G; Egidi MF; Comai G; Vischini G; Bottici V; Elisei R; Viola D
J Endocrinol Invest; 2021 Jan; 44(1):95-103. PubMed ID: 32363491
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
Milling RV; Grimm D; Krüger M; Grosse J; Kopp S; Bauer J; Infanger M; Wehland M
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347815
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
[TBL] [Abstract][Full Text] [Related]
14. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma.
Rimassa L; Danesi R; Pressiani T; Merle P
Cancer Treat Rev; 2019 Jul; 77():20-28. PubMed ID: 31195212
[TBL] [Abstract][Full Text] [Related]
15. [Side effect management of tyrosine kinase inhibitors in urology : Gastrointestinal side effects].
Lieb V; Rink M; Sikic D; Keck B
Urologe A; 2016 Jun; 55(6):805-12. PubMed ID: 27146873
[TBL] [Abstract][Full Text] [Related]
16. Managing tyrosine kinase inhibitors side effects in thyroid cancer.
Krajewska J; Paliczka-Cieslik E; Jarzab B
Expert Rev Endocrinol Metab; 2017 Mar; 12(2):117-127. PubMed ID: 30063430
[TBL] [Abstract][Full Text] [Related]
17. Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis.
Chen YC; Chen JH; Hsieh FI
J Chin Med Assoc; 2024 Jan; 87(1):48-57. PubMed ID: 37991373
[TBL] [Abstract][Full Text] [Related]
18. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
Ye X; Zhu Y; Cai J
J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
[TBL] [Abstract][Full Text] [Related]
19. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
20. Effects and Role of Multikinase Inhibitors in Thyroid Cancer.
Laursen R; Wehland M; Kopp S; Pietsch J; Infanger M; Grosse J; Grimm D
Curr Pharm Des; 2016; 22(39):5915-5926. PubMed ID: 27306093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]